Carregant...
Left Behind? Drug Discovery in Extensive Stage Small Cell Lung Cancer
Systemic therapy and subsequent survival for patients with extensive stage small cell lung cancer (SCLC) are poor and have remained unchanged in the last quarter century. To improve outcomes in these patients, a new drug development paradigm must be adopted that moves away from empiricism and instea...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4184801/ https://ncbi.nlm.nih.gov/pubmed/24529447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2013.12.010 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|